Financial Performance - Total revenue for the year ended December 31, 2025, was HKD 117,397,000, a decrease of 25.4% compared to HKD 157,235,000 in 2024[2] - Gross profit for 2025 was HKD 51,496,000, down 47.7% from HKD 98,344,000 in 2024[2] - The company reported a profit before tax of HKD 82,184,000, a significant recovery from a loss of HKD 175,157,000 in the previous year[2] - Net profit for the year was HKD 82,809,000, compared to a loss of HKD 174,286,000 in 2024[2] - Basic and diluted earnings per share for 2025 were HKD 0.3595, a turnaround from a loss of HKD 0.7565 per share in 2024[3] - The group reported a total external segment revenue of HKD 117,397,000 for 2025, compared to HKD 157,235,000 in 2024, indicating a decline of 25.3%[18] - The group’s net profit before tax for 2025 was HKD 82,184,000, a significant recovery from a loss of HKD 175,157,000 in 2024[18] - The group recorded a profit of approximately HKD 82,800,000 for the year ended December 31, 2025, compared to a loss of HKD 174,300,000 in 2024, primarily due to a reversal of impairment losses on receivables amounting to approximately HKD 50,900,000[47] Assets and Liabilities - Total assets decreased to HKD 538,470,000 in 2025 from HKD 754,717,000 in 2024, reflecting a reduction of 28.7%[4] - Current liabilities decreased to HKD 255,760,000 in 2025 from HKD 512,763,000 in 2024, a reduction of 50.1%[4] - The company's total equity increased to HKD 333,659,000 in 2025 from HKD 249,252,000 in 2024, representing a growth of 33.9%[5] - The company has no non-current liabilities related to bonds in 2025, compared to HKD 50,000,000 in 2024[5] - The group’s total assets as of December 31, 2025, amounted to HKD 602,220,000, down from HKD 824,714,000 in 2024, a decrease of 27%[22] - The total liabilities as of December 31, 2025, were HKD 268,561,000, compared to HKD 575,462,000 in 2024, reflecting a reduction of 53.3%[22] - The total trade payables amounted to HKD 38,656,000, an increase from HKD 27,530,000 in 2024[38] Revenue Breakdown - Revenue from medical products increased to HKD 78,544,000 in 2025 from HKD 72,234,000 in 2024, representing an increase of 4.5%[12] - Total revenue from customer contracts for 2025 was HKD 84,406,000, up from HKD 77,782,000 in 2024, marking a growth of 8.3%[12] - The group’s total revenue from the securities brokerage and asset management services segment was HKD 1,768,000 in 2025, down from HKD 3,907,000 in 2024, a decrease of 54.8%[18] - The group’s total revenue from lending and other financial services was HKD 31,893,000 in 2025, compared to HKD 76,607,000 in 2024, a decline of 58%[18] - Revenue from Hong Kong for 2025 is HKD 100,001,000, slightly up from HKD 99,872,000 in 2024[24] - Revenue from Europe dropped significantly from HKD 46,723,000 in 2024 to HKD 10,792,000 in 2025, a decline of 76.9%[24] Cash Flow and Investments - As of December 31, 2025, the company's cash and cash equivalents decreased by approximately HKD 32,800,000 to about HKD 58,300,000 compared to HKD 91,100,000 as of December 31, 2024[48] - The company sold a total of 1,560,000 shares of a subsidiary on January 12, 2026, for approximately HKD 3,300,000, expecting a realizable gain of about HKD 200,000[56] - The company did not have any pledged assets as of December 31, 2025[50] Employee and Governance - The total number of employees decreased to 101 as of December 31, 2025, from 149 in the previous year[54] - The company maintained compliance with the corporate governance code throughout the year ended December 31, 2025[61] Dividends and Provisions - The company did not recommend a final dividend for the year ending December 31, 2025, consistent with 2024[30] - The board did not recommend the distribution of a final dividend for the year ended December 31, 2025, consistent with the previous year[55] - The company’s tax provision for the current year in China was HKD 81,000, down from HKD 397,000 in 2024[28] Risk and Strategy - The group faced credit concentration risk as 62% of all loans to margin clients were from the top five margin clients[36] - The company plans to continue its focus on investment holding and may explore new strategies for market expansion and product development in the future[6] - The group plans to focus on expanding its financial services, including corporate financing and asset management, amid a challenging economic environment[45]

（於百慕達註冊成立之有限公司） （股份代號：1225） 正面盈利預告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Lerado Financial Group Company Limited 隆成金融集團有限公司 本公告乃由隆成金融集團有限公司（「本公司」，連同其附屬公司統稱「本集團」） 根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條及香港法例 第571章證券及期貨條例（「證券及期貨條例」）第XIVA部項下的內幕消息條文而刊 發。 本公司董事（「董事」）會（「董事會」）謹此通知本公司股東及潛在投資者，根據對 本集團最新管理賬目之初步審閱，預期本公司截至二零二五年十二月三十一日止 年度之綜合溢利為淨溢利約83百萬港元，而截至二零二四年十二月三十一日止年 度則錄得淨虧損約174百萬港元。該溢利主要由於(i) 截至二零二五年十二月三十一 日止年度按公平值計入損益（「按公平值計入損益」）之金融資產錄得公平值收益 約48百萬港元；及( ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Lerado Financial Group Company Limited 隆成金融集團有限公司 （於百慕達註冊成立之有限公司） 執行董事 何觀禮 香港，二零二六年三月十九日 於本公告日期，執行董事為陳俊傑先生、何觀禮女士及梁錦波先生；及獨立非執行 董事為余達志先生、楊海琿先生及林全智先生。 隆成金融集團有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，董事 會會議將於二零二六年三月三十一日（星期二）舉行，藉以（其中包括）考慮及批 准本公司及其附屬公司截至二零二五年十二月三十一日止年度之全年業績，以及 考慮派發末期股息（如有）。 代表董事會 隆成金融集團有限公司 （股份代號：1225） 董事會會議日期 ...

呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01225 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000,000 | HKD | | 0.01 HKD | | 5,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | | | 本月底結存 | | | 500,000,000,000 | HKD | | 0.01 HKD | | 5,000,000,000 | 本月底法定/註冊股本總額： HKD 5,000,000,000 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 隆成金融集團有限公司 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01225 | 說明 普通股 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | 500,000,000,000 | HKD | | 0.01 | HKD | | 5,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | | | 本月底結存 | | 500,000,000,000 | HKD | | 0.01 | HKD | | 5,000,000,000 | 本月底法定/註冊股本總額 ...

Group 1 - The company, 隆成金融 (01225), announced the sale of a total of 1.56 million shares of 景联集团 at a total price of approximately 3.3 million HKD, excluding transaction costs [1] - The average price per share for the sale was approximately 2.11 HKD [1] - The company expects to realize a gain of approximately 200,000 HKD from this transaction [1]

Group 1 - The core announcement is that Longcheng Financial (01225) plans to sell a total of 1.56 million shares of Jinglian Group in the public market, with a total consideration of approximately HKD 3.3 million, excluding transaction costs [1] - The average selling price of Jinglian Group shares is approximately HKD 2.11 per share [1] - The group expects to realize a gain of approximately HKD 200,000 from this sale [1]

Group 1 - The company, 隆成金融 (01225.HK), announced the sale of a total of 1.56 million shares of 景联集团 at an average price of approximately HKD 2.11 per share, resulting in a total consideration of about HKD 3.3 million, excluding transaction costs [1] - The company expects to realize a gain of approximately HKD 200,000 from this sale [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Lerado Financial Group Company Limited 隆成金融集團有限公司 （於百慕達註冊成立之有限公司） （股份代號：1225） 有關出售上市證券的須予披露交易 出售事項 董事會謹此宣佈，於二零二六年一月十二日，本公司於公開市場出售合共1,560,000 股景聯集團股份，總代價約為3,300,000港元（不包括交易成本），景聯集團股份 平均價格約為每股2.11港元。由於出售事項，本集團預期可變現收益約200,000港 元。 由於出售事項在公開市場上進行，故本公司並不知悉景聯集團股份買方的身份。 據董事經作出一切合理查詢後所深知、盡悉及確信，景聯集團股份的買方及彼等 各自的最終實益擁有人均為獨立第三方。 已出售資產 本集團出售的景聯集團股份相當於景聯集團於本公告日期已發行股本總額約0.53%。 於出售事項完成後，本集團不再持有任何景聯集團股份。 進行出售事項的理由及裨益 根據景聯 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 隆成金融集團有限公司 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01225 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000,000 | HKD | | 0.01 HKD | | 5,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | | | 本月底結存 | | | 500,000,000,000 | HKD | | 0.01 HKD | | 5,000,000,000 | 本月底法定/註冊股本總 ...